Author

Fabio Cataldi

EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Fabio Cataldi  et al.

EFFICACY AND SAFETY OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF CANNABINOID RECEPTOR 2, FOR THE TREATMENT OF ABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RESULTS FROM A PHASE 2B RANDOMIZED STUDY
EFFICACY AND SAFETY OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF CANNABINOID RECEPTOR 2, FOR THE TREATMENT OF ABDOMINAL PAIN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: RESULTS FROM A PHASE 2B RANDOMIZED STUDY

Fabio Cataldi  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Fabio Cataldi  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Fabio Cataldi  et al.

Item 1 - 4 / 4
1